EDITORIAL

IgG4-Related Disease and Malignancy
Mikulicz's disease (MD) has been included within the diagnosis of primary Sjögren's syndrome (SS), but it represents a unique condition involving the enlargement of the lacrimal and salivary glands and characterized by few autoimmune reaction (1) . Glucocorticoid treatment is effective for the clinical improvement of this disease (2) . Now it is considered that MD is quite a different disease from primary SS (1), and a type of IgG4-related disease (IgG4-RD) (3). IgG4-RD is characterized by a swelling of the affected organs along with elevated levels of serum IgG4, and abundant infiltration of IgG4-bearing plasma cells and fibrosis. IgG4-RD is a new concept of systemic and chronic inflammation (3), and usually includes MD, autoimmune pancreatitis (AIP) (4), and IgG4-related tubulointerstitial nephritis (5) . IgG4-RD is an important disease for clinical physicians to discriminate from cancers and other rheumatic diseases.
On the other hand, recent focus has been on the relationship between IgG4-RD and malignancies. IgG4-RD with pancreatic cancer has often been reported in cases of AIP (6, 7) . It is known that positron emission tomography (PET) is very useful for systemic evaluation in IgG4-RD (8, 9) . Whenever we make a diagnosis of IgG4-RD, we consult PET images. In some instances, we are presented with cases involving abnormal accumulation at the lesion sites outside of the involved organs; this is known as organic dysfunction of IgG4-RD. Upon further examination, we often find that the lesion is cancer. In such instances, PET is very useful for detecting cancer. Our previous study (SMART database: Sapporo Medical University and Related institutes database for investigation and best treatments of IgG4-related disease) demonstrated that malignancies occurred in 10.4% of IgG4-RD cases. Using the database of national cancer registries in the monitoring of cancer incidence in Japan (2005) (10), the standardized incident ratio (SIR) for cancers in male patients with IgG4-RD was 331.1, and in female patients with IgG4-RD, 471.6. The total was 383.0. It was approximately 3.5 times higher than the inci-dence of cancer in the general population (11) .
Malignancies as complications of IgG4-RD are divided into lymphoma and non-lymphoid tumors. Lymphoma includes mucosa-associated lymphoid tissue (MALT) lymphoma and non-Hodgkin lymphoma. Lymphoma can present as a background of chronic inflammation. In SS, antigenic activation of B cells, together with oncogenic events, including p53 inactivation and bcl-2 activation, may play important roles in B cell monoclonal proliferation and malignant transformation (12) . It is reported that the SIR for lymphoma in patients with SS was higher, 8.7 to 48.1 (13) (14) (15) . It is suggested that this rate for lymphoma in MD is also high as well as in SS.
In this issue of Internal Medicine, Uehara et al (16) report a 66-year-old man, who suffered from IgG4-RD, and performed autopsy. The patient had been followed as MD and IgG4-related pseudo-inflammatory tumor in the pelvis, but autopsy disclosed the coexistence of diffuse large B cell lymphoma. It could not be considered that lymphoma was complicated at the diagnosis of IgG4-RD. It is suggested that an activated B cell caused malignant transformation in the background of chronic inflammation. Therefore, it is critical to recognize the risk of lymphoma in MD as well as SS.
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